Plant Name: Aglaia perviridis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.753E-09 | 5.053E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.576E-08 | 1.734E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.582E-08 | 1.734E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.952E-07 | 4.592E-04 | ALDH1A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GFER, HMGCR, HSD17B10 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.109E-07 | 4.592E-04 | CA12, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.146E-07 | 1.217E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.175E-07 | 1.318E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 8.836E-07 | 1.318E-03 | CA9, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, RELA |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 9.686E-07 | 1.318E-03 | CA9, CASP1, CNR2, CYP1A1, CYP1B1, HMGCR, RELA |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.278E-06 | 1.637E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, HMGCR |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.597E-06 | 1.830E-03 | ALDH1A1, CYP19A1, CYP1A1, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.245E-06 | 2.444E-03 | CASP1, CNR2, CYP1A1, CYP1A2, RELA |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.274E-06 | 2.971E-03 | CA12, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.148E-06 | 2.971E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.856E-06 | 3.343E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.049E-06 | 4.704E-03 | CA12, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.636E-06 | 5.481E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.377E-05 | 8.102E-03 | CNR2, CYP1A1, CYP1B1, HMGCR, RELA |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.587E-05 | 8.713E-03 | ALDH1A1, CYP19A1, CYP1A1, CYP1B1, HMGCR |
| BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 1.601E-05 | 8.713E-03 | CASP1, CYP1A1, HMGCR, RELA |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.796E-05 | 9.538E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.129E-07 | 8.015E-06 | CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.076E-06 | 9.647E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.047E-06 | 1.428E-04 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.837E-07 | 1.007E-05 | CA12; CA7; CA9 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.074E-05 | 1.526E-04 | CASP7; CASP1; RELA |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.780E-05 | 2.107E-04 | CYP1A2; ALDH1A1; CYP1A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.525E-05 | 2.430E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.739E-05 | 2.430E-04 | CASP7; CASP1; RELA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.579E-05 | 2.824E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.608E-04 | 1.851E-03 | CYP1A2; ALDH1A1; CYP1A1; HMGCR; CYP19A1; HSD17B10 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 9.334E-04 | 6.025E-03 | CASP1; RELA |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.175E-03 | 6.953E-03 | CASP1; RELA |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.421E-03 | 1.735E-02 | CASP7; RELA |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.109E-03 | 1.152E-02 | CASP1; RELA |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.475E-03 | 2.429E-02 | CASP7; RELA |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.339E-03 | 2.648E-02 | CASP7; RELA |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 8.428E-03 | 3.149E-02 | CASP1; RELA |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.791E-03 | 3.073E-02 | CASP7; HSD17B10 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.994E-03 | 1.890E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HMGCR |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | HMGCR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; CASP1 |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | HMGCR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| NA: NA | Dyslipidemia | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |